Chromanol derivatives - A novel class of CETP inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 1, 2011, Pages 488-491

  Vakalopoulos, Alexandros ^a   Schmeck, Carsten ^a   Thutewohl, Michael ^b   Li, Volkhart ^a   Bischoff, Hilmar ^a   Lustig, Klemens ^a   Weber, Olaf ^a   Paulsen, Holger ^a   Elias, Harry ^a  

^a BAYER PHARMA AG   (Germany)

^b Merck and Cie   (Switzerland)

Author keywords

CETP inhibitor; Chromanols; HDL; Torcertrapib

Indexed keywords

ANACETRAPIB; BAY 381315; BAY 605521; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHROMANOL DERIVATIVE; DALCETRAPIB; TORCETRAPIB; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SYNTHESIS; HUMAN; IC 50; LIPOPHILICITY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BENZOPYRANS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHROMANS; DOGS; HUMANS; MICE; MICE, TRANSGENIC; RATS; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650512118     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.10.110     Document Type: Article

References (28)

1. H. Bays, and E.A. Stein Expert Opin. Pharmacother. 4 2003 1901
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 1. (Adult Treatment Panel III) final report Circulation 2002, 106, 3143.
3. S.M. Grundy, J.I. Cleeman, C.N.B. Merz, H.B. Brewer Jr., L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith Jr., and N.J. Stone Circulation 110 2004 227 [Erratum: Circulation 2004, 110, 763]
4. S.A. Doggrell Expert Opin. Investig. Drugs 10 2001 1755
5. M.J. Chapman, G. Assmann, J.-C. Fruchart, J. Shepherd, C. Sirtori European Consensus Panel Curr. Med. Res. Opin. 20 2004 1253 and references cited therein
6. G. Assmann, H. Schulte, A. Von Eckardstein, and Y. Huang Atherosclerosis 124 1996 S11
7. P. Linsel-Nitschke, and A.R. Tall Nat. Rev. Drug. Discov. 4 2005 193 [Erratum: Nat. Rev. Drug. Disc. 2005, 4, 698]
8. W.E. Boden Am. J. Cardiol. 86 2000 19L
9. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, F.H. Faas, E. Linares, E.J. Schaefer, G. Schectman, T.J. Wilt, and J. Wittes N. Engl. J. Med. 341 1999 410
10. J. Shepherd, J. Betteridge, L. Van Gaal European Consensus Panel Curr. Med. Res. Opin. 21 2005 665
11. R.W. Clark, T.A. Sutfin, R.B. Ruggeri, A.T. Willauer, E.D. Sugarman, G. Magnus-Aryitey, P.G. Cosgrove, T.M. Sand, R.T. Wester, J.A. Williams, M.E. Perlman, and M.J. Bamberger Arterioscler. Thromb. Vasc. Biol. 24 2004 490
12. M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, L.T. Bloedon, A.G. Digenio, R.W. Clark, J.P. Mancuso, and D.J. Rader N. Engl. J. Med. 350 2004 1505
13. H. Shinkai Expert Opin. Ther. Patents 19 2009 1229
14. J.A. Sikorski Expert Opin. Ther. Patents 16 2006 753
15. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J.P. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.-C. Tardif, D.D. Waters, C.L. Shear, J.H. Revkin, K.A. Buhr, M.R. Fisher, A.R. Tall, and B. Brewer N. Engl. J. Med. 357 2007 2109
16. S.E. Nissen, J.-C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, W.T. Duggan, W. Ruzyllo, W.B. Bachinsky, G.P. Lasala, and E.M. Tuzcu N. Engl. J. Med. 356 2007 1304
17. It was suggested that torcetrapib induces more proinflammatory lesions in mice of a less stable phenotype than atorvastatin: W. De Haan, De. Vries-van, J. der Weij, J.W.A. Van der Hoorn, T. Gautier, C.C. Van der Hoogt, M. Westerterp, J.A. Romijn, J.W. Jukema, L.M. Havekes, H.M.G. Princen, and P.C.N. Rensen Circulation 117 2008 2515
18. C.P. Cannon, H.M. Dansky, M. Davidson, A.M. Gotto Jr., E.A. Brinton, A.L. Gould, M. Stepanavage, S.X. Liu, S. Shah, J. Rubino, P. Gibbons, A. Hermanowski-Vosatka, B. Binkowitz, Y. Mitchel, and P. Barter Am. Heart J. 158 2009 513.e3
19. E.A. Stein, E.S.G. Stroes, G. Steiner, B.M. Buckley, A.M. Capponi, T. Burgess, E.J. Niesor, D. Kallend, and J.J.P. Kastelein Am. J. Cardiol. 104 2009 82
20. H. Paulsen, C. Schmeck, A. Brandes, G. Schmidt, J. Stoltefuss, S.N. Wirtz, M. Lögers, P. Naab, K.-D. Bremm, H. Bischoff, D. Schmidt, S. Zaiss, and S. Antons Chimia 58 2004 123
21. H. Paulsen, S. Antons, A. Brandes, M. Lögers, S.N. Müller, P. Naab, C. Schmeck, S. Schneider, and J. Stoltefuss Angew. Chem., Int. Ed. 38 1999 3373
22. C. Schmeck, H. Gielen-Haertwig, A. Vakalopoulos, H. Bischoff, V. Li, G. Wirtz, and O. Weber Bioorg. Med. Chem. Lett. 20 2010 1740
23. B. Di Simone, D. Savoia, E. Tagliavini, and A. Umani-Ronchi Tetrahedron: Asymmetry 6 1995 301
24. A.K. Ghosh, S. Fidanze, and C.H. Senanayake Synthesis 1998 937
25. 3 pH 7.4 containing 10 μl of CETP (1 mg/ml) and 3 μl of a solution of the substance to be tested (dissolved in 10% DMSO/1% BSA). Two hundred microliters of the SPA-streptavidin bead solution (TRKQ 7005) are then added, incubated further with shaking for 1 h and then measured in a scintillation counter. Corresponding incubations with 10 μl of buffer, 10 μl of CETP serve as controls.
26. Y. Mori, and N. Morishima Bull. Soc. Chem. Jpn. 67 1994 236
27. S. Castillon, A. Dessinges, R. Faghih, G. Lukacs, A. Olesker, and T.T. Thang J. Org. Chem. 50 1985 4913
28. Data published in WO2007/107243.